跳至主要内容
临床试验/CTRI/2025/07/091429
CTRI/2025/07/091429尚未招募3 期

Role of duloxetine in the prevention of chemotherapy induced peripheral neuropathy in patients recieving paclitaxel

Stanley medical College and hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年8月5日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
60
试验地点
1
主要终点
To study the effect of duloxetine in the prevention of chemotherapy induced peripheral neuropathy in patients receiving paclitaxel

研究概览

简要总结

To study the effect of duloxetine in the prevention of chemotherapy induced peripheral neuropathy in patients receiving paclitaxel

To compare dose modification of paclitaxel due to peripheral neuropathy in each arm

20% dose reduction for grade I and II

discontinue drug for grade III and IV

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • All patients recieving paclitaxel with any Cancer diagnosis with any stage will and able to comply with all study requirements with signed and written consent.

排除标准

  • Concurrent disease that may lead to peripheral neuropathy like diabetes mellitus rheumatologic disease vitamin B12 deficiency any allergy to duloxetine patients receiving ccb alfa blocker with psychiatric disorders any bleeding manifestations and pregnant and lactating women.

结局指标

主要结局

To study the effect of duloxetine in the prevention of chemotherapy induced peripheral neuropathy in patients receiving paclitaxel

时间窗: 12 WEEKS

次要结局

  • To compare dose modification of paclitaxel due to peripheral neuropathy in each arm(3 months)

研究者

发起方
Stanley medical College and hospital
申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Navjot Kaur

Stanley medical College and hospital

研究点 (1)

Loading locations...

相似试验